Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133259 | 0.79 | CYP3A4 (0.46) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL1264765 | 0.77 | POLB (0.54) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL14895927 | 0.72 | PDPK1 (0.40) | SCN2AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL9397783 | 0.70 | ALDH1A1 (0.72) | SCN2AMAPTMEN1KMT2AKDM4E | |
| SCHEMBL22095684 | 0.70 | HSD17B10 (0.46) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL2857970 | 0.70 | ROCK1 (0.50) | MEN1KMT2AALDH1A1ACHETDP1 | |
| SCHEMBL28030105 | 0.70 | CLK1 (0.45) | MAPTMEN1KMT2AKDM4EPOLB | |
| SCHEMBL14896334 | 0.69 | HTT (0.35) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL14908385 | 0.69 | GABRP (0.36) | MEN1KMT2AKDM4ELMNAPOLB | |
| SCHEMBL28257786 | 0.69 | TSHR (0.54) | MAPTMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594505-A4 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7122559-B2 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1594505-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004072101-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004072101-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | F7, SERPINE1, HABP2 | SCN2A 1587/4885MAPT 4322/4885MEN1 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.